Drug
Pegvaliase clinical trials
Also written BMN 165.
- studies test it
- 10
- open now
- 1
- in phase 3
- 4
- first study started
- 2008
Keep track of what changes. Save the pegvaliase studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
Development codes
Other names
Studies by the year they started
10 studies that test it; most in 2013 (2)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 2 |
| 2018 | 1 |
| 2022 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 4
- Phase 3
- 4
- Phase 4
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 0
Studies
Open first, then newest update. How each study uses pegvaliase is read from its arms, and is right about nine times in ten.
Testing it · 10
- Immune Modulation During Palynziq® Treatment in Adults (IMPALA)RecruitingPhase 4BioMarin PharmaceuticalNCT07477691Written as Pegvaliase
- Study to Evaluate the Safety and Efficacy of Pegvaliase in Adolescents (Ages 12-17) With PhenylketonuriaActive, not recruitingPhase 3BioMarin PharmaceuticalNCT05270837Written as Pegvaliase
- Safety and Efficacy of Self Administered Injections of Pegvaliase (>40mg/Day Dose) in Adults With PKUCompletedPhase 3BioMarin PharmaceuticalNCT03694353Written as Pegvaliase
- Long-Term Extension of Previous rAvPAL-PEG Protocols in Subjects With PKU (PAL-003)CompletedPhase 2BioMarin PharmaceuticalNCT00924703Written as rAvPAL-PEG
- Phase 3 Study to Evaluate the Efficacy & Safety of Self-Administered Injections of BMN165 by Adults With PKUCompletedPhase 3BioMarin PharmaceuticalNCT01889862Written as BMN165 20mg/day
- A Study to Evaluate Subcutaneously Administered rAvPAL-PEG in Patients With Phenylketonuria for 24 WeeksCompletedPhase 2BioMarin PharmaceuticalNCT01560286Written as BMN 165 (rAvPAL-PEG)
- An Open-Label Phase 3 Study of BMN 165 for Adults With PKU Not Previously Treated w/ BMN 165CompletedPhase 3BioMarin PharmaceuticalNCT01819727Written as BMN 165
- Safety, Tolerability, and Efficacy Study of rAvPAL-PEG Administered Daily in Subjects With Phenylketonuria (PKU)CompletedPhase 2BioMarin PharmaceuticalNCT01212744Written as rAvPAL-PEG
- Dose-Finding Study to Evaluate the Safety, Efficacy, & Tolerability of Multiple Doses of rAvPAL-PEG in Subjects With PKUCompletedPhase 2BioMarin PharmaceuticalNCT00925054Written as rAvPAL-PEG 0.001 mg/kg
- Safety and Tolerability Study of rAvPAL-PEG to Treat PhenylketonuriaCompletedPhase 1BioMarin PharmaceuticalNCT00634660Written as rAvPAL-PEG
Codes
What other systems call pegvaliase · ClinicalTrials.gg INT001007
- MeSH (NLM) C000629004pegvaliaseConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) N6UAH27EUVPEGVALIASEConfirmed FDA, NLM, Wikidata
- RxNorm 2046360One source FDA
- Wikidata Q27284634pegvaliaseConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C174744PegvaliaseOne source FDA
- DrugBank DB12839One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000629004 | pegvaliase | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | N6UAH27EUV | PEGVALIASE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2046360 | — | One source FDA |
| Wikidata | Q27284634 | pegvaliase | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C174744 | Pegvaliase | One source FDA |
| DrugBank | DB12839 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.